Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 11/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.62 |
| ▸ | PI4KA | P42356 | 3/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.62 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.62 |
| ▸ | AHCY | P23526 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9343605 | 0.91 | ADORA2A (0.67) | ADCY5ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL9343603 | 0.91 | ADORA2A (0.67) | ADCY5ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL9309056 | 0.87 | ADORA2A (0.69) | ADCY5ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL9308668 | 0.87 | ADORA2A (0.69) | ADCY5ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL10394463 | 0.85 | ADCY5 (0.55) | ADCY5ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL10475247 | 0.85 | ADCY5 (0.55) | ADCY5ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6045780 | 0.85 | ADCY5 (1.00) | ADCY5ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6045742 | 0.85 | ADCY5 (1.00) | ADCY5ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6045662 | 0.85 | ADCY5 (1.00) | ADCY5ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6045752 | 0.85 | ADCY5 (1.00) | ADCY5ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115193410-B | Modified activated carbon and preparation method and application thereof | 中国矿业大学(北京) | 2023-09-22 | — | — | CN | disclosed |
| CN-114835839-B | Polymer isotope Raman probe and preparation and application thereof | 华中科技大学 | 2023-07-04 | — | — | CN | disclosed |
| CN-115193410-A | Modified activated carbon and preparation method and application thereof | 中国矿业大学(北京) | 2022-10-18 | — | — | CN | disclosed |
| CN-114835839-A | Polymer isotope Raman probe and preparation and application thereof | 华中科技大学 | 2022-08-02 | — | — | CN | disclosed |
| EP-2922859-B1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIV CORK (IE) | 2021-05-05 | — | — | EP | disclosed |
| US-9822137-B2 | Phosphonucleosides useful in the treatment of viral disorders | UNIVERSITY COLLEGE CORK (IE) | 2017-11-21 | — | — | US | disclosed |
| US-9822137-B2 | Phosphonucleosides useful in the treatment of viral disorders | UNIVERSITY COLLEGE CORK (IE) | 2017-11-21 | — | — | US | disclosed |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-15 | — | — | US | disclosed |
| WO-2014079903-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIVERSITY COLLEGE CORK (IE) | 2014-05-30 | — | — | WO | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-4916224-A | VIRICIDES FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1990-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | RNASEH1, NSUN3, RNASEL | ADCY5 3118/4885ADORA2A 2420/4885ADORA3 1657/4885 |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | ENTPD5, PNP, MTAP | ADCY5 3734/4885ADORA2A 2042/4885ADORA3 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.